Suppr超能文献

转化生长因子-{beta} 协同诱导细胞因子信号转导抑制因子 3 和白血病抑制因子抑制破骨细胞凋亡。

Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis.

机构信息

Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.

出版信息

Endocrinology. 2010 Apr;151(4):1713-22. doi: 10.1210/en.2009-0813. Epub 2010 Feb 24.

Abstract

Local release of TGF-beta during times of high bone turnover leads to elevated levels within the bone microenvironment, and we have shown that TGF-beta suppresses osteoclast apoptosis. Therefore, understanding the influences of TGF-beta on bone resorbing osteoclasts is critical to the design of therapies to reduce excess bone loss. Here we investigated the mechanisms by which TGF-beta sustains suppression of osteoclast apoptosis. We found TGF-beta rapidly increased leukemia inhibitory factor (LIF) expression and secretion by phosphorylated mothers against decapentaplegic-dependent and -independent signaling pathways. TGF-beta also induced suppressor of cytokine signaling 3 (SOCS3) expression, which was required for TGF-beta or LIF to promote osteoclast survival by. Blocking LIF or SOCS3 blocked TGF-beta promotion of osteoclast survival, confirming that LIF and SOCS3 expression are necessary for TGF-beta-mediated suppression of osteoclast apoptosis. Investigation of the mechanisms by which LIF promotes osteoclast survival revealed that LIF-induced expression of Bcl-X(L) and repressed Bcl-2 interacting domain expression by activating MAPK kinase, AKT, and nuclear factor-kappaB pathways. Suppression of Janus kinase/signal transducer and activator of transcription signaling further increased Bcl-X(L) expression and enhanced osteoclast survival, supporting that this pathway is not involved in prosurvival effects of TGF-beta and LIF. These data show that TGF-beta coordinately induces LIF and SOCS3 to promote prosurvival signaling. This alters the ratio of prosurvival Bcl2 family member Bcl-X(L) to proapoptotic family member Bcl-2 interacting domain, leading to prolonged osteoclast survival.

摘要

在骨转换活跃时期,局部 TGF-β 的释放会导致骨微环境中 TGF-β 水平升高。我们已经证实,TGF-β 可抑制破骨细胞凋亡。因此,了解 TGF-β 对破骨细胞的影响对于设计减少骨丢失的治疗方法至关重要。在这里,我们研究了 TGF-β 持续抑制破骨细胞凋亡的机制。我们发现 TGF-β 通过磷酸化的 Mothers against decapentaplegic (SMAD)依赖性和非依赖性信号通路,迅速增加白血病抑制因子(LIF)的表达和分泌。TGF-β 还诱导了细胞因子信号转导抑制因子 3(SOCS3)的表达,这是 TGF-β 或 LIF 促进破骨细胞存活所必需的。阻断 LIF 或 SOCS3 可阻止 TGF-β 促进破骨细胞存活,证实了 LIF 和 SOCS3 的表达对于 TGF-β 介导的破骨细胞凋亡抑制是必要的。研究 LIF 促进破骨细胞存活的机制表明,LIF 通过激活 MAPK 激酶、AKT 和核因子-κB 通路诱导 Bcl-X(L)的表达,并抑制 Bcl-2 相互作用域的表达。抑制 Janus 激酶/信号转导和转录激活因子信号进一步增加了 Bcl-X(L)的表达并增强了破骨细胞的存活,这表明该途径不参与 TGF-β 和 LIF 的促存活作用。这些数据表明,TGF-β 协调诱导 LIF 和 SOCS3 以促进促生存信号。这改变了促生存 Bcl2 家族成员 Bcl-X(L)与促凋亡家族成员 Bcl-2 相互作用域的比例,导致破骨细胞存活时间延长。

相似文献

2
TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.
Exp Cell Res. 2008 Sep 10;314(15):2725-38. doi: 10.1016/j.yexcr.2008.06.006. Epub 2008 Jun 13.
4
The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells.
Haematologica. 2008 Jul;93(7):1039-48. doi: 10.3324/haematol.12402. Epub 2008 May 19.
7
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia.
Nature. 2008 Jul 10;454(7201):221-5. doi: 10.1038/nature07019. Epub 2008 Jun 11.
9
Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.
J Biol Chem. 2009 Aug 28;284(35):23397-404. doi: 10.1074/jbc.M109.019372. Epub 2009 Jul 1.

引用本文的文献

3
New insights into pathogenesis: Role of leukemia inhibitory factor.
Front Cell Infect Microbiol. 2022 Oct 18;12:1029178. doi: 10.3389/fcimb.2022.1029178. eCollection 2022.
4
Novel insights into the coupling of osteoclasts and resorption to bone formation.
Semin Cell Dev Biol. 2022 Mar;123:4-13. doi: 10.1016/j.semcdb.2021.10.008. Epub 2021 Oct 30.
5
New Insights Into Osteoclast Biology.
JBMR Plus. 2021 Aug 30;5(9):e10539. doi: 10.1002/jbm4.10539. eCollection 2021 Sep.
6
Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology.
Noncoding RNA. 2020 Sep 9;6(3):37. doi: 10.3390/ncrna6030037.
7
Sclerostin expression in trabecular bone is downregulated by osteoclasts.
Sci Rep. 2020 Aug 13;10(1):13751. doi: 10.1038/s41598-020-70817-1.
8
Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases.
Front Physiol. 2020 Feb 5;11:47. doi: 10.3389/fphys.2020.00047. eCollection 2020.
9
Positive and negative regulators of osteoclast apoptosis.
Bone Rep. 2019 Oct 21;11:100225. doi: 10.1016/j.bonr.2019.100225. eCollection 2019 Dec.

本文引用的文献

1
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.
PLoS One. 2009;4(4):e5275. doi: 10.1371/journal.pone.0005275. Epub 2008 Apr 16.
3
Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.
Cancer Sci. 2009 Jan;100(1):71-81. doi: 10.1111/j.1349-7006.2008.01012.x. Epub 2008 Nov 25.
5
TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.
Exp Cell Res. 2008 Sep 10;314(15):2725-38. doi: 10.1016/j.yexcr.2008.06.006. Epub 2008 Jun 13.
6
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia.
Nature. 2008 Jul 10;454(7201):221-5. doi: 10.1038/nature07019. Epub 2008 Jun 11.
8
Transforming growth factor-beta enables NFATc1 expression during osteoclastogenesis.
Biochem Biophys Res Commun. 2008 Feb 1;366(1):123-8. doi: 10.1016/j.bbrc.2007.11.120. Epub 2007 Dec 3.
9
A delicate balance: TGF-beta and the tumor microenvironment.
J Cell Biochem. 2007 Jul 1;101(4):851-61. doi: 10.1002/jcb.21149.
10
Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic.
J Biol Chem. 2006 Dec 1;281(48):36683-90. doi: 10.1074/jbc.M607374200. Epub 2006 Oct 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验